JY-1-106 is a BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. References: Perri M, Yap JL, Fletcher S, Cione E, Kane MA. Therapeutic potential of Bcl-x(L)/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment. Oncol Lett. 2018 May;15(5):7231-7236. doi: 10.3892/ol.2018.8258. Epub 2018 Mar 14. PubMed PMID: 29849791; PubMed Central PMCID: PMC5962833.

纯度：≥98%